List of Contract Research Companies in Switzerland - 12

The decoding of the proteome is revolutionizing the way diseases are diagnosed, treated, and prevented. Biognosys invents and provides patented proteomics solutions at the quality, scale, and speed required to transform R&D, clinical trials, and clinical decision making. Our Solutions We offer a versatile portfolio of proprietary proteomics services, software, and kits. We make these widely available for pharmaceutical and biotechnology researchers and proteomics experts. Our solutions provide a multi-dimensional view of protein expression, function, and structure in all major sample types – cells, tissues, or body fluids – across human and non-human species. Our Technology Biognosys is the leading inventor and developer of mass spectrometry-based proteomics solutions. With market leading proteome coverage and sample throughput we enable simultaneous quantification of thousands of proteins across thousands of samples. Our Facility From our global headquarters just outside of Zurich, we operate one of the largest high-end mass spectrometry laboratories worldwide for Large-Scale Discovery Proteomics contract research. Our Data Competence Biognosys has analyzed a vast amount of proteomics data and developed an industry-leading understanding of the proteome. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. Global Presence Founded in 2008 as a spin-off from the lab of proteomics pioneer Ruedi Aebersold at ETH Zurich, Biognosys today is an established leader in next-generation proteomics. With employees based across Switzerland, Europe, and US, and an extensive network of collaborators and distributors, Biognosys supports a global customer base of life science researchers across industry and academia.

Critical Raw Materials and Services for Diagnostics, Vaccines and Pharmaceuticals. Where Chemistry meets Biology, Products meet Services and Innovation meets Quality, Biosynth is at the Edge of Innovation. Biosynth's mission is to supply critical raw materials and services to the pharmaceutical and diagnostic industries. Biosynth strives to de-risk its customer's supply chains. Our expertise and capability runs across Complex Chemicals, Peptides and Key Biologics all from one trusted partner. Biosynth is a life sciences reagents, custom synthesis and manufacturing services company. We are by scientists, for scientists, securing supply chains with consistent quality, across the globe. We manufacture and source a vast range of chemical and biochemical products, and take pride in delivering products that others cannot. We are experts in complex chemistry, peptides and key biological raw materials. We provide a full range of products and services to support life science research and development, with more than a million products in our research catalog and hundreds of complex manufacturing service projects. The trusted supplier, manufacturer and partner for the pharmaceutical, life science and diagnostic sectors, along with customers across food, agrochemistry and cosmetics, we have facilities across three continents and a rapid global distribution network. We produce chemicals on the milligram to ton scale, and at ISO 9001 and GMP, with peptides at mg to multikilogram scale. Biosynth's services and products include enzyme development and biocatalysis, reagents for in vitro diagnostics and bioconjugation chemistry. Biosynth is owned, among others by KKR, Ampersand and Senior Management.

CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates. Beyond our services, we also provide high-quality Cholesterol and Vitamin D analogs. CARBOGEN AMCIS is owned by Dishman Carbogen Amcis Limited, (India). Learn more about us: www.carbogen-amcis.com

With more than 45 years’ experience in the pharmaceutical industry, Swiss-based CERBIOS is specialized in the manufacturing of Generic APIs&HPAPIs alongside with finished formulations based on its own probiotic strain and exclusive CDMO services for HPAPIs, ADCs and recombinant proteins. 𝐏𝐡𝐚𝐫𝐦𝐚 𝐏𝐫𝐨𝐝𝐮𝐜𝐭𝐬 Cerbios portfolio covers a wide range of drug substances including reduced folates such as Calcium Folinate (Leucovorin Calcium), Calcium Levofolinate, Folinic Acid, 5-Methyl-Tetrahydrofolic Acid Calcium Salt, Sodium Folinate, as well as other folates manufactured exclusively for customers. Starting from 1993 Cerbios specialized further in the commercial manufacturing of HPAPIs, with a particular focus on Vitamin D Derivatives, (analogues). Cerbios has also a long standing experience in the probiotics field. For more than 40 years Cerbios produces its finished pharmaceutical drug based on proprietary strain Enterococcus faecium SF68®, for treatment of diarrhea and dysbiosis by antibiotics. Due to the unique characteristics of SF68®, Cerbios recently marketed two new Food Supplements for the management of ACNE & Seborrheic dermatitis and to boost immune response; other new formulations/application are in development phase. 𝐂𝐃𝐌𝐎 Services Cerbios is the ideal partner from clinical to commercial supply of API, HPAPIs, Payloads, ADCs, Proteins and Antibodies. Services offered include Process & Analytical Development, Scale-up and Clinical Supply, Industrial Validation, Commercial Supply, Full CMC Regulatory Support. Within its ADC dedicated division -Proveo (TM)- Cerbios has leveraged the combined experience in Payloads and recombinant proteins to offer an end-to-end solution for Antibody Drug Conjugates (ADCs). 𝐀𝐧𝐢𝐦𝐚𝐥 𝐇𝐞𝐚𝐥𝐭𝐡 Products CERBIOS offers a range of products for animal feed or veterinary application including probiotic feed additives Cernivet® LBC G35, Cernivet® LBC ME5 PET, Cernivet® LBC M10, Cernivet® LBC M20 plus.

Clinerion, a wholly owned subsidiary of TriNetX LLC, accelerates clinical research and medical access to treatments for patients. We use proprietary, patented technologies for analysis of live electronic health record (EHR) data from our global network of partner hospitals to generate real-world data (RWD), which can be used for investigation into disease epidemiology, the patient journey and outcomes, and patient care metrics. Clinerion's Patient Network Explorer platform radically improves the efficiency and effectiveness of clinical trials by offering data-driven protocol optimization, site feasibility evaluation, and search and identification for patient recruitment – in real-time. Among other uses, we provide solutions for increasing diversity in clinical trials and identification of rare disease patients. Clinerion's new Federated Machine Learning Platform enables the training and validation of machine learning (ML) algorithms on our global RWD network. Apart from the contributions to drug development this platform targets to develop preventive care for patients before they reach a critical stage. Clinerion operates on the principle of "privacy by design" and complies fully with international patient privacy and data security regulations. Clinerion is headquartered in Switzerland. Clinerion website: www.clinerion.com Clinerion's Patient Network Explorer: www.clinerion.com/index/OverviewOurSolutions/ClinerionPatientNetworkExplorer

​evitria is specialized in CHO-based transient expression of antibodies (including bispecific and fusion antibodies). With a track record of more than 120,000 successful antibody production runs for our clients, we can offer fast and reliable project execution at high quality standards (all production facilities in Switzerland). You can benefit from our expertise and unique focus when looking to entrust a partner with your complete antibody production or to manage capacity bottlenecks with single projects.

Looking for a trusted partner in the development of cell lines and manufacturing processes? Look no further. With over 20 years of experience, we specialize in high-yielding (5-14 g/L), GMP-ready, CHO, and HEK293 cell lines for the production of biologics, biosimilars, and gene therapy (AAV, Adenovirus). We have a proven track record of expressing all types of proteins, including bi-specific mAb, Fc-fusions, viral proteins, cytokines, and more. Our team of scientists is ready to support your project from start to finish, including process development, analytical methods, scale-up, tox-batches, and Master Cell Banking. At our company, we pride ourselves on our commitment to quality and customer satisfaction. Contact us today to see how we can help you achieve your goals and be your trusted partner in cell line and process development.

The KD Pharma Group is a CDMO that develops products in the pharmaceutical and nutraceutical space. It is also the worldwide leading producer of API for Omega-3 pharmaceuticals and has built a similar market-leading position in Omega-3 nutraceuticals, formulation and encapsulation services, with over 500 employees and a presence in the UK, Norway, Germany, Switzerland and the US. The KD Pharma Group employs state-of-the-art technology which is protected by numerous patents.

LYO-X provides strategic consulting and PK/PD modelling services dedicated to the preclinical and clinical development of biologics and cell based therapies. Our speciality are drug formats at the scientific edge: bi-specifics, antibody-drug conjugates, scFv's, nanobodies and cell based therapies. Whatever your therapeutic approach, we have the expertise in biology, pharmacology, mathematical modeling and drug development to provide tailored support for your unique program. We apply systems pharmacology for target assessment, format selection, compound design, candidate selection, design and analysis of preclinical PK/PD and GLP toxicology studies, first in human dose selection, dose / regimen finding studies and paediatric drug development. Our customers are biotechnology start-ups, pharmaceutical companies and CROs. LYO-X is part of the iBx Network. The iBx Network provides integrated services in toxicology, pharmacology, preclinical and clinical development in combination with modelling and simulation. For more information see www.lyo-x.com

Preclin Biosystems is a biotechnology company that offers a comprehensive in vivo preclinical testing platform for the identification and validation of lead candidate therapeutics.

ten23 health is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups for the development, manufacture, and testing of tomorrow’s medicines. Our sites in Visp and Basel 🇨🇭 support our clients in developing differentiated, stable, usable, and safe injectable treatments for patients. More about us: www.ten23.health